argenx

Stories

argenx buys a peptide chemistry company to build oral immunology drugs

Acquirer

Every medicine argenx sells today reaches patients by infusion or injection. On Nov. 9, 2026, the Dutch immunology company agreed to pay $550 million in cash for a Santa Cruz company whose chemistry is built to make pills instead.

Updated 1 hour ago

argenx completes Forte Biosciences takeover, adds first-in-class anti-CD122 antibody

Money Moves

As of August 2026: Acquirer; Forte now a wholly owned subsidiary

argenx, a Belgian immunology company, closed its $2.2 billion takeover of Forte Biosciences on August 27, 2026. Forte is now a wholly owned subsidiary and its shares have been delisted from Nasdaq.

Updated Aug 27